Cutting Edge mRNA Pipeline in Infectious Diseases & Oncology

mRNA Vaccine Approach Program Discovery Proof-of-Concept Pre-IND Phase 1 Phase 2 Phase 3 Partners
OncologyOncology
Precision Medicine PTX-102 Solid Tumors – Precision Antigens
 
logo
  PTX-103 Glioblastoma – Common Antigens
 
 
Immunotargeting PTX-104 Indication Undisclosed – APC Targeted multivalent vaccine
 
 
Universal Cancer Vaccine PTX-105 Solid Tumors – Target Undisclosed
 
Undisclosed
Infectious DiseasesInfectious Diseases
Booster Vaccine PTX-COVID19-B COVID-19 – Spike – Phase 2 Endpoint Met
 
Program Paused

Post Exposure Vaccine PTX-203 Shingles
 
 
Prophylactic Vaccine PTX-201 Pan-Sarbecovirus– Multiantigen
 
 
  PTX-205 Highly Pathogenic Influenza
 
 
  PTX-204 Malaria – Multiantigen
 
logo
  PTX-206 Salmonella - Multiantigen
 
logo
Animal HealthAnimal Health
Prophylactic Vaccine PTX-301 Highly Pathogenic Influenza
 
Undisclosed